Biomarkers of prognosis in patients with differentiated thyroid cancer: Results from the DECISION trial.

2016 
6059Background: Sorafenib (SOR) is a multikinase inhibitor approved to treat locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) refractory to radioactive iodine treat...
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    4
    Citations
    NaN
    KQI
    []